Mirabegron: A Review in Overactive Bladder Syndrome

Mirabegron: A Review in Overactive Bladder Syndrome Drugs https://doi.org/10.1007/s40265-018-0924-4 ADIS DRUG EVALUATION Emma D. Deeks Springer International Publishing AG, part of Springer Nature 2018 Abstract The first-in-class b -adrenoceptor agonist mir- status, although data in men (from a phase 4 study and TM abegron is indicated in the EU (Betmiga ), Japan (Be- phase 3 trial subanalyses) are variable; additional studies in TM tanis ) and several other countries for the management of older and male OAB patients are awaited with interest. overactive bladder (OAB) syndrome. Evidence for its use Although further longer-term efficacy and tolerability data in this setting includes several large phase 3 trials. Com- would be beneficial, current clinical evidence indicates that pared with placebo, oral mirabegron for 12 weeks reduced mirabegron provides an alternative to antimuscarinics for the frequency of micturition and generally also that of the management of OAB in adults, including those for incontinence, with other benefits including reduced whom antimuscarinics have proven unsuitable. urgency, increased void volume and improved health related quality-of-life (HR-QOL). Mirabegron comparisons versus tolterodine are descriptive; however, in a 12-week Mirabegron: clinical considerations in OAB powered comparison versus solifenacin in patients dissat- isfied with antimuscarinic efficacy, mirabegron did not First b -adrenoceptor agonist approved for OAB http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drugs Springer Journals

Mirabegron: A Review in Overactive Bladder Syndrome

Drugs , Volume OnlineFirst – Jun 4, 2018
Loading next page...
 
/lp/springer_journal/mirabegron-a-review-in-overactive-bladder-syndrome-02rNhWwGVx
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0012-6667
eISSN
1179-1950
D.O.I.
10.1007/s40265-018-0924-4
Publisher site
See Article on Publisher Site

Abstract

Drugs https://doi.org/10.1007/s40265-018-0924-4 ADIS DRUG EVALUATION Emma D. Deeks Springer International Publishing AG, part of Springer Nature 2018 Abstract The first-in-class b -adrenoceptor agonist mir- status, although data in men (from a phase 4 study and TM abegron is indicated in the EU (Betmiga ), Japan (Be- phase 3 trial subanalyses) are variable; additional studies in TM tanis ) and several other countries for the management of older and male OAB patients are awaited with interest. overactive bladder (OAB) syndrome. Evidence for its use Although further longer-term efficacy and tolerability data in this setting includes several large phase 3 trials. Com- would be beneficial, current clinical evidence indicates that pared with placebo, oral mirabegron for 12 weeks reduced mirabegron provides an alternative to antimuscarinics for the frequency of micturition and generally also that of the management of OAB in adults, including those for incontinence, with other benefits including reduced whom antimuscarinics have proven unsuitable. urgency, increased void volume and improved health related quality-of-life (HR-QOL). Mirabegron comparisons versus tolterodine are descriptive; however, in a 12-week Mirabegron: clinical considerations in OAB powered comparison versus solifenacin in patients dissat- isfied with antimuscarinic efficacy, mirabegron did not First b -adrenoceptor agonist approved for OAB

Journal

DrugsSpringer Journals

Published: Jun 4, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off